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Abstract: 
Despite the progress that has been made in diagnosis and treatment of early stage breast cancer a substantial 
proportion of patients still go on to develop incurable distant metastatic cancer. Estrogen receptors, progesterone 
receptors, human epidermal receptor-2 expression in breast cancer are associated with development of distant 
metastases. Most commonly observed site for distant metastases are liver, lung, bone, brain. The purpose of present 
study is to examine the hormone receptor status on development of distant metastases (liver, lung, bone, brain). The 
purpose of the present study focused mainly impact of hormone receptors such as estrogen receptor, progesterone 
receptor and human epidermal growth factor receptors in metastatic breast cancer were distant organs involved were 
liver, lung, bone, brain, recurrence and its pharmaceutical management based on receptor status in a tertiary care 
hospital. Based on the receptor presence and absence the treatment alters. Hence it is necessary to study the hormone 
receptor status which helps in management of disease and to prevent further progression of disease. 
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INTRODUCTION: 
Cancer is the uncontrolled growth and spread of cells. 
It can affect almost any part of the body. The growths 
often invade surrounding tissue and can metastasize to 
distant sites (such as lung, liver, bone, brain). Many 
cancers can be prevented by avoiding exposure to 
common risk factors, such as tobacco smoke. In 
addition, a significant proportion of cancers can be 
cured, by surgery, radiotherapy or chemotherapy, 
especially if they are detected early.[1] The most 
common type of cancer is breast cancer, with 271,270 
new cases expected in the United States in 2019.[2] 
Cancer cases in India (2010-2020) of NCRP indicate 
that there will be more than 100,000 estimated number 
of Breast Cancer cases annually in India based on the 
data from NCRP in Bangalore.[3]About two-thirds of 
breast cancers are hormone receptor positive, which 
means that they need female hormones (oestrogen 
and/or progesterone) to grow and 
reproduce.Hormones like estrogen and progesterone 
are chemicals produced by glands in the body. 
Normally, these hormones help regulate body cycles, 
like menstruation. However, sometimes these same 
hormones can cause cancer to grow. Cancer is called 
ER-positive (ER+) if it has receptors for hormone 
estrogen which receives the signals from estrogen and 
promotes its growth, just like normal cells. Similarly, 
the cancer is PR-positive (PR+) if it has receptors for 
hormone progesterone. Similarly, HER2-positive 
status of the breast carcinoma means that HER2 gene 
is making too many HER2 proteins. HER2 proteins are 
receptors on breast cells.The pathologist will perform 
tests on the breast cancer cells to determine if they 
have receptors that feed on estrogen or progesterone, 
stimulating their growth. 
 
Immunohistochemical Scoring System for 
Estrogen Receptor, Progesterone Receptor, and 
Human Epidermal Growth Factor Receptor 
2/Neu[4]  
 
Allred system of scoring for estrogen receptor and 
progesterone receptor  
ER and PR are nuclear receptors. In Allred system of 
scoring, score 0-5 is given to the cells depending on 
the proportion of cells which are stained (proportion 
score [PS]) and score 0-3 is given depending on the 
intensity of staining (intensity score [IS]) [Tables 1 
and 2]. By adding the PS and IS, we can calculate the 
final Allred score (PS + IS = AS) [Table 3].  
 
Scoring for human epidermal growth factor 
receptor 2/neu overexpression  
HER2/neu is a cell membrane receptor and depending 
on the intensity of staining a score of 0-3 is given to 
the cells [Table 4].  
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AIM: 
To study the prognostic effect of Hormone receptor 
status on pattern of metastasis in breast cancer and its 
pharmaceutical management. 
 
OBJECTIVES:  
To assess the hormone receptor status(ER, PR, HER-
2) in metastatic breast cancer.  
 
METHODOLOGY: 
A prospective observational study was carried out in 
government general hospital, Guntur for duration of 6 
months i.e., September 2018 to February 2019 after 
obtaining approval from institutional ethics 
committee. The patients were screened based on 
inclusion and exclusion criteria. Inclusion criteria 
includes Patients whose origin of cancer (primary 
lesion) involved is breast, Patients who are diagnosed 
with metastatic breast cancer, Breast cancer metastasis 
patients with either ER/PR/HER-2 positive or 
negative, Patients who are willing to participate in the 
study, Female patients with age >18yrs, Patients who 
are taking chemotherapy and hormonal therapy for 
metastatic breast cancer, Patients who are willing for 
regular follow up. Exclusion criteria includes Patients 
whose origin of cancer is other than breast, Patients 
with other than metastatic breast cancer, Patients who 
are <18yrs of age, Those who are not willing to 
participate in the study, Female patients with 
pregnancy, Patients who are not willing for regular 
follow up. Patients who satisfied inclusion criteria 
were included in the study. After including the subjects 
into the study the data was collected in the designed 
data collection form. The hormonal receptor status 
{ER/PR/HER-2} in metastatic breast cancer was 
assessed based on pathology reports. The data 
obtained was entered in advanced Microsoft excel 
spread sheet and evaluated. For statistical analysis, 
Graph Pad Prism 8.1.0 was used and one sample t-test 
and paired t-test was done with the 95% confidence 
interval at alpha value 0.05 and the p-values <0.05 are 
considered to be significant. 
RESULTS: 
Our study found that there is no significant association 
of family history in development of 
metastatic breast cancer as shown in table 5.
Table 5:Family history Vs Number of Subjects 
Family history Number of subjects (N=52) 
Yes 3(5.77%) 
No 49(94.23%) 
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Table 6: Age Vs No.of Subjects  
The below table represents the information regarding distribution of subjects within the age groups 21-80. 
 
 
 
 
 
 
 
Table 7: Menstrual irregularities Vs number of subjects 
Our study found there is no significant association of menstrual irregularities in development of metastasis in breast 
cancer. 
 
Menstrual irregularities Number of subjects (N=52) 
Yes 19(36.54%) 
No 33(63.46%) 
 
Table 8: Metastatic site Vs number of subjects 
 
The below table shows the information regarding the metastatic site which indicates the effected sites. 
 
 
 
Age of the subject Number of subjects (N=52) 
21-30 2(3.85%) 
31-40 7(13.46%) 
41-50 18(34.62%) 
51-60 20(38.45%) 
61-70 3(5.77%) 
71-80 2(3.85%) 
Type of metastasis Number of subjects (N=52) 
Bone 16(30.77%) 
Liver 9(17.31%) 
Lung 6(11.57%) 
Brain 3(5.77%) 
Recurrence 9(17.31%) 
Bone, recurrence 1(1.92%) 
Liver, recurrence 1(.92%) 
Lung, bone 3(5.77%) 
Liver, brain 1(1.92%) 
Liver, lung 1(1.92%) 
Bone, liver 1(1.92%) 
Lung, bone, liver 1(1.92%) 
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Table 9: Hormonal receptor status in different metastatic breast cancer Vs Number of subjects 
 
The below table shows the hormone receptor status in different metastatic breast cancer patients. 
 
Types of 
metastatic 
site 
ER
+
/PR
+ 
/Her2
+
 
ER
+
/PR
+ 
/Her2
-
 
ER
-
/PR
-
/Her2
+
 
ER
-
/PR
-
/Her2
-
 
ER
+
/PR
-
/Her2
+
 
ER
+
/PR
-
/Her2
-
 
ER
-
/PR
+ 
/Her2
+
 
ER
-
/PR
+ 
/Her2
-
 
Total 
(n) 
Bone 3(18.75%) 8(50%) 2(12.5%) 2(12.5%) 0(0%) 0(0%) 0(0%) 1(6.25%) 16 
Liver 3(33.33%) 3(33.33%) 1(11.11%) 2(22.22%) 0(0%) 0(0%) 0(0%) 0(0%) 9 
Lung 1(16.67%) 2(33.33%) 0(0%) 2(33.33%) 0(0%) 0(0%) 0(0%) 1(16.67%) 6 
Brain 0(0%) 1(33.33%) 0(0%) 2(66.67%) 0(0%) 0(0%) 0(0%) 0(0%) 3 
Recurrence 1(11.11%) 5(55.56%) 2(22.22%) 1(11.11%) 0(0%) 0(0%) 0(0%) 0(0%) 9 
Bone, 
recurrence 
0(0%) 0(0%) 1(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1 
Liver, 
recurrence 
0(0%) 0(0%) 1(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1 
Lung, bone 0(0%) 2(66.67%) 0(0%) 1(33.33%) 0(0%) 0(0%) 0(0%) 0(0%) 3 
Liver, brain 0(0%) 0(0%) 1(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1 
Liver, lung 0(0%) 0(0%) 0(0%) 1(100%) 0(0%) 0(0%) 0(0%) 0(0%) 1 
Bone, liver 0(0%) 0(0%) 1(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1 
Lung, bone, 
liver 
0(%) 0(0%) 0(0%) 1(100%) 0(0%) 0(0%) 0(0%) 0(0%) 1 
A p value (<0.0001****) was considered to extremely significant  
 
DISCUSSION: 
A non-experimental prospective observational study 
was carried out on- “IMPACT OF HORMONE 
RECEPTOR STATUS (ER,PR,HER-2) ON 
PATTERN OF METASTASIS IN BREAST 
CANCER AND ITS PHARMACEUTICAL 
MANAGEMENT INTERTIARY CARE 
HOSPITAL.” 52 patients met the inclusion criteria 
and were includedin the study. The data obtained was 
tabulated and analysed.The information regarding 
distribution of patients within age groups of 21 to 80 
years.Majority of patients were found within 51 60 
years (38.54%) followed by 41-50 years(34.62%), 31-
40 years (13.46%) and 61-70 years (5.77%), 21-30 
years (3.85%) , 71-80 years(3.85%). Based on the 
results obtained our study revealed that 16 (30.76%) 
subjects of the 52subjects the first distant metastasis 
was to bone.Out of the 18 subjects whose first 
metastasis wasto the viscera, the organ most often 
involved was the liver (n=9; 17.30%) followed by lung 
(n=6; 11.53%) and brain (n=3; 5.77%). These findings 
were in concordance with study doneby LindaVona-
Davisetal., (2014) conducted a study on “Breast 
Cancer Pathology,Receptor Status, and Patterns of 
Metastasis in a Rural Appalachian Population.”[5] And 
9 out of52 subjects were diagnosed with 
recurrence(17.30%), remaining 9 subjects were 
diagnosedwith multiple site metastasis i.e., out of 9 
(17.30%) 3 subjects were diagnosed with lung,bone 
(5.77%) and bone, recurrence(n=1 ;1.92%), liver, 
recurrence (n=1 ; 1.92%), liver, brain (n=1 ; 
1.92%),liver, lung (n=1 ; 1.92%) bone, liver (n=1 ; 
1.92%) lung, bone,liver(n=1; 1.92%).Our study main 
objective was to assess the hormone receptor 
status(ER, PR, HER-2) onpattern of metastasis in 
breast cancer. Tumors were grouped as HR-
positive/HER2- positive(HR+/HER2+) , HR-
negative/HER2-positive (HR /HER2+) , HR-
positive/HER2- negative(HR+/HER2-) , HR-
negative/HER2-negative (HR-/HER2-) and also 
estrogen receptornegative /progesterone receptor 
positive / HER2 negative ( ER-/PR+/HER2-). We 
analysedhormonal receptor status by using t- test. 
Based on the results out of 52 subjects, 16 subjectswho 
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were diagnosed with carcinoma of breast with bone 
metastases in those hormonereceptor status is 
observed as HR+/HER2- (n=8 ;50%) , HR+/HER2+ 
(n=3 ; 18%) , HR-/HER2+ (n=2 ; 12.5%) , HR-/HER2- 
(n=2, 12.5%) and ER-/PR+/HER2- (n=1 ; 6.25%) 
(P=<0.0001). Out of 52 subjects, 9 subjects who were 
diagnosed with carcinoma of breast withliver 
metastases in those hormone receptor status is 
observed as HR+/HER2+ (n=3; 33.3%),HR+/HER2- 
(n=3; 33.3%), HR-/HER2-(n=2; 22.2%) HR-/HER2+ 
(n=1; 11.1%). Out of 52 subjects, 6 subjects who were 
diagnosed carcinoma of breast with lung metastasis in 
thosehormone receptor status is observed as HR-
/HER2- (n=2; 33.3%) HR+/HER2- (n=2; 
33.3%)HR+/HER2+ (n=1; 16.6%), ER-/PR+/HER2 
(n=1; 16.6%) (P=<0.0001) and out of 52subjects, 3 
subjects who were diagnosed with carcinoma of breast 
with brain metastasis inthose hormone receptor status 
is observed as HR-/HER2- (n=2; 66.6%) and 
HR+/HER2-(n=1; 33.3%) (P=<0.0001). Out of 52 
subjects, 9 subjects who were diagnosed with 
breastcancer with recurrence in those hormone 
receptor status is observed as HR+/HER2- 
(n=5;55.5%), HR-/HER2+ (n=2; 22.2%), HR-/HER2- 
(n=1; 11.1%), HR+/HER2+ (n=1; 
11.1%)(P=<0.0001%). Out of 52 subjects, 9 subjects 
who were diagnosed with multiple sitemetastasis, for 
bone, recurrence (n=1) HR/HER2+ (n=1; 100%) 
(P=0.0001). Liver,recurrence (n=1) with HR-/HER2+ 
(n=1; 100%) and 3 subjects diagnosed with lung, 
bonemetastasis having HR+/HER2- (n=2, 66.6%), 
HR-/HER2 (n=1; 33.3%) (P=<0.0001); liver,brain 
metastasis with HR-/HER2+ (n=1; 100%); liver, lung 
metastasis with HR-/HER2-(n=1;100%); bone, liver 
metastasis with HR-/HER2+ (n=1; 100%); Lung, 
bone, liver metastasis= with HR-/HER2- (n=1; 100%) 
(P=<0.0001).Our study also found that there is no 
significant association (94.23%) withfamily history 
for the development of metastasis in breast cancer and 
also there is nosignificant association (63.4%) with 
menstrual irregularities for the development 
ofmetastasis in breast cancer. 
 
CONCLUSION: 
Based on the results obtained our study concludes that 
bone is the major site of metastasis in breast cancer 
followed by recurrence, liver, lung, brain .in bone 
metastasis majority ofsubjects having receptor status 
HR+/HER2- (n=8; 50%) and in liver HR+/HER2+ 
(n=3;33.3%) HR+/HER2- (n=3; 33.3%) HR-/HER2- 
(n=2; 22.2%) was reported. In lungHR+/HER2-(n=2; 
33.3%) HR-/HER2- (n=2; 33.3%), in brain majorly 
observed receptorstatus was triple negative HR-
/HER2- (n=2; 66.6%), in recurrence condition 
HR+/HER2-(n=5; 55.5%) was majorly observed.In 
case of multiple site metastasis i.e., bone, recurrence 
and liver, recurrence werewith receptor status HR-
/HER2+ and in lung, bone with receptor status 
HR+/HER2- (n=2; 66.6%) and in liver, brain and 
bone, liver metastases HR-/HER2+ was observed. In 
liver,lung and lung, bone, liver metastasis the receptor 
status HR-/HER2- was found (P=<0.0001). 
 
 
LIMITATION:  
This study included only 52 patients to assess the 
“IMPACT OF HORMONE RECEPTOR STATUS 
(ER, PR, HER-2) ON PATTERN OF METASTASIS 
IN BREAST CANCER AND ITS 
PHARMACEUTICAL MANAGEMENT IN 
TERTIARY CARE HOSPITAL: APROSPECTIVE 
OBSERVATIONAL STUDY”. 3 subjects were 
excluded because ofunavailability of hormonal 
receptor status .This study has to be further extended 
with morenumber of patients to derive at a better 
conclusion. 
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